RAS: Target for Cancer Therapy

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Investigation

• Publication date

  2008-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1080/07357900802087275PMID 18798058
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice.

  2007cited by this paper
• Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

  2007cited by this paper
• BRAF mutation predicts sensitivity to MEK inhibition

  2006cited by this paper
• Lipid posttranslational modifications. Farnesyl transferase inhibitors.

  2006cited by this paper
• The tuberous sclerosis complex.

  2006cited by this paper
• Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

  2006cited by this paper
• Surprising Dependency for Retinoblastoma Protein in Ras-Mediated Tumorigenesis

  2006cited by this paper
• Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors Published, JLR Papers in Press, November 8, 2005.

  2006cited by this paper
• Ras, PI(3)K and mTOR signalling controls tumour cell growth

  2006cited by this paper
• Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.

  2005cited by this paper
• Signaling interplay in Ras superfamily function.

  2005cited by this paper
• Post-prenylation-processing enzymes as new targets in oncogenesis

  2005cited by this paper
• A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody “EMD72000 (Matuzumab)” administered weekly in Japanese patients with advanced solid tumors; safety, PK and PD results of skin biopsies

  2005cited by this paper
• Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance.

  2005cited by this paper
• Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.

  2005cited by this paper
• Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

  2004cited by this paper
• Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf.

  2004influential reference
• Signaling through the epidermal growth factor receptor during the development of malignancy.

  2004cited by this paper
• Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor.

  2004cited by this paper
• Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD).

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• RAS oncogenes: the first 30 years

  2003cited by this paper
• Isoprenylcysteine carboxyl methyltransferase activity modulates endothelial cell apoptosis.

  2003cited by this paper
• Ras signalling on the endoplasmic reticulum and the Golgi

  2002cited by this paper
• Absence of the CAAX Endoprotease Rce1: Effects on Cell Growth and Transformation

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Phospholipase C(epsilon): a novel Ras effector.

  2001cited by this paper
• Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.

  2001cited by this paper
• Regulation of a novel human phospholipase C, PLCepsilon, through membrane targeting by Ras.

  2001cited by this paper
• Regulation of the Forkhead Transcription Factor AFX by Ral-Dependent Phosphorylation of Threonines 447 and 451

  2001cited by this paper
• Ras and Rho regulation of the cell cycle and oncogenesis.

  2001cited by this paper
• Phospholipase Cϵ: a novel Ras effector

  2001cited by this paper
• Regulation of a Novel Human Phospholipase C, PLCε, through Membrane Targeting by Ras*

  2001cited by this paper
• Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines.

  2000cited by this paper
• Specificity and mechanism of action of some commonly used protein kinase inhibitors.

  2000cited by this paper
• Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

  1999cited by this paper
• Hyperactive Ras as a therapeutic target in neurofibromatosis type 1.

  1999cited by this paper
• Cellular survival: a play in three Akts.

  1999cited by this paper
• Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes.

  1998cited by this paper
• CaaX converting enzymes.

  1998cited by this paper
• Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.

  1998cited by this paper
• Discovery of novel nonpeptide tricyclic inhibitors of Ras farnesyl protein transferase.

  1997cited by this paper
• Antitumor 8-chlorobenzocycloheptapyridines: a new class of selective, nonpeptidic, nonsulfhydryl inhibitors of ras farnesylation.

  1997cited by this paper
• Protein prenylation: molecular mechanisms and functional consequences.

  1996cited by this paper
• Stimulation of Membrane Ruffling and MAP Kinase Activation by Distinct Effectors of RAS

  1996cited by this paper
• Novel Tricyclic Inhibitors of Farnesyl Protein Transferase

  1995cited by this paper
• Ras recruits Raf‐1 to the plasma membrane for activation by tyrosine phosphorylation.

  1995cited by this paper
• Phosphatidylinositol-3-OH kinase direct target of Ras

  1994cited by this paper
• Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes.

  1994cited by this paper
• Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane

  1994cited by this paper
• Proteins regulating Ras and its relatives

  1993cited by this paper
• Increased radioresistance of ejras‐transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation

  1993cited by this paper
• Function and regulation of ras.

  1993cited by this paper
• Pathways of Ras function: connections to the actin cytoskeleton.

  1993cited by this paper
• Altered growth of human colon cancer cell lines disrupted at activated Ki-ras.

  1993cited by this paper
• The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors.

  1992cited by this paper
• Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA.

  1991cited by this paper
• Regulators and effectors of ras proteins.

  1991cited by this paper
• All ras proteins are polyisoprenylated but only some are palmitoylated.

  1989cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper
• ras genes.

  1987cited by this paper
• Three human transforming genes are related to the viral ras oncogenes.

  1983cited by this paper

• Association of HMGB1 expression with prognosis of non-small cell lung cancer: a systematic review and meta-analysis

  2026cites this paper
• Elucidating Ras protein as a dual therapeutic target for inflammation and cancer: a review

  2025cites this paper
• Structural insights, regulation, and recent advances of RAS inhibitors in the MAPK signaling cascade: a medicinal chemistry perspective.

  2025cites this paper
• KRAS G12C Inhibition in Solid Tumors: Biological Breakthroughs, Clinical Evidence, and Open Challenges

  2025cites this paper
• Predicting PROTAC-targeted Degradation and Designing Androgen Receptor Degraders with AiPROTAC

  2025cites this paper
• Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer

  2024cites this paper
• KRAS inhibitors in drug resistance and potential for combination therapy

  2024cites this paper
• Anticancer and chemopreventive potential of Morinda citrifolia L. bioactive compounds: A comprehensive update

  2024cites this paper
• KRAS G12C inhibitor combination therapies: current evidence and challenge

  2024cites this paper
• 6-Gingerol Induced Apoptosis and Cell Cycle Arrest in Glioma Cells via MnSOD and ERK Phosphorylation Modulation

  2024cites this paper
• Synthesis and Anticancer Potentials of 1,8-Naphthyridine Analogues: A Review of Literature

  2023cites this paper
• Small molecular inhibitors for KRAS-mutant cancers

  2023cites this paper
• Significance of miRNAs on the thyroid cancer progression and resistance to treatment with special attention to the role of cross-talk between signaling pathways.

  2023cites this paper
• Indoloquinoline-Mediated Targeted Downregulation of KRAS through Selective Stabilization of the Mid-Promoter G-Quadruplex Structure

  2022cites this paper
• DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs

  2022cites this paper
• Role of protein S-Glutathionylation in cancer progression and development of resistance to anti-cancer drugs.

  2021cites this paper
• Signal Transduction Inhibition

  2020cites this paper
• Tumour heterogeneity revealed by unsupervised decomposition of dynamic contrast-enhanced magnetic resonance imaging is associated with underlying gene expression patterns and poor survival in breast cancer patients

  2019cites this paper
• Follistatin-Like 1 Promotes Bleomycin-Induced Pulmonary Fibrosis through the Transforming Growth Factor Beta 1/Mitogen-Activated Protein Kinase Signaling Pathway

  2018cites this paper
• Discovery of the actinoplanic acid pathway in Streptomyces rapamycinicus reveals a genetically conserved synergism with rapamycin

  2018cites this paper
• STK33 Promotes Growth and Progression of Pancreatic Cancer as a Critical Downstream Mediator of HIF1α.

  2017cites this paper
• Intrinsic protein disorder in oncogenic KRAS signaling

  2017cites this paper
• Cigarette smoke induced urocystic epithelial mesenchymal transition via MAPK pathways

  2017cites this paper
• Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer

  2016influential citation
• Metabolic Labeling with an Alkyne-modified Isoprenoid Analog Facilitates Imaging and Quantification of the Prenylome in Cells

  2016cites this paper
• Synthetic isoprenoid analogues for the study of prenylated proteins: Fluorescent imaging and proteomic applications.

  2016cites this paper
• The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer

  2016cites this paper
• Investigation of the mechanisms terminating growth factor induced Ras activation

  2016cites this paper
• Silencing the wild-type and mutant K-ras increases the resistance to 5-flurouracil in HCT-116 as a colorectal cancer cell line

  2015cites this paper
• Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets

  2015cites this paper
• The genomic landscape of phaeochromocytoma

  2015cites this paper
• The management of thyroid nodules and cancer in the molecular era

  2015cites this paper
• High-Affinity Interaction of the K-Ras4B Hypervariable Region with the Ras Active Site

  2015cites this paper
• Downregulation of Ras GTPase‑activating protein 1 is associated with poor survival of breast invasive ductal carcinoma patients.

  2015cites this paper
• Caenorhabditis elegans: A Model System for Anti-Cancer Drug Discovery and Therapeutic Target Identification

  2014cites this paper
• Rapid Analysis of Protein Farnesyltransferase Substrate Specificity Using Peptide Libraries and Isoprenoid Diphosphate Analogues

  2014cites this paper
• Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials

  2014cites this paper
• Knockdown of mutated H-Ras V12 expression induces chemosensitivity of hepatocellular carcinoma cells to cisplatin treatment in vitro and in nude mouse xenografts.

  2014cites this paper
• Desired Alteration of Protein Affinities: Competitive Selection of Protein Variants Using Yeast Signal Transduction Machinery

  2014cites this paper
• The Role of Prenylation in Vascular Calcification

  2014influential citation
• PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.

  2014cites this paper
• MicroRNA 17-92 Cluster Mediates ETS1 and ETS2-Dependent RAS-Oncogenic Transformation

  2014cites this paper
• Combined mutational analysis of RAS, BRAF, PIK3CA, and TP53 genes in Taiwanese patients with oral squamous cell carcinoma.

  2014cites this paper
• The Role of the ATR-CHEK1 Pathway in Therapeutic Resistance Resulting from Distal 11q Loss in Carcinoma Cells

  2013cites this paper
• Resistance to Targeted Therapies in Melanoma: New Insights

  2013cites this paper
• Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas

  2013cites this paper
• Essential Role of Cdc42 in Ras-Induced Transformation Revealed by Gene Targeting

  2012cites this paper
• RAS oncogenic signal upregulates EZH2 in pancreatic cancer.

  2012cites this paper
• Ras Signaling Pathway in the Chemopreventive Action of Different Ratios of Fish Oil and Corn Oil in Experimentally Induced Colon Carcinogenesis

  2012cites this paper
• LEOPARD Syndrome: Clinical Features and Gene Mutations

  2012cites this paper
• [The role of glucose transporter 1 (GLUT1) in the diagnosis and therapy of tumors].

  2012cites this paper
• Targeted Therapies in Melanoma: Knowledge, Resistance and Perspectives

  2012cites this paper
• Statin Treatment Increases Lifespan and Improves Cardiac Health in Drosophila by Decreasing Specific Protein Prenylation

  2012cites this paper
• The mechanism of HAMLET-induced cell death - cellular signalling, oncogenes and clinical perspectives

  2012cites this paper
• Yeast two-hybrid methods and their applications in drug discovery.

  2012cites this paper
• Analysis of binding site hot spots on the surface of Ras GTPase.

  2011cites this paper
• Hepatocellular carcinoma with persistent hepatitis B virus infection shows unusual downregulation of Ras expression and differential response to Ras mediated signaling

  2011cites this paper
• Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: A new drug combination for cancer therapy

  2011cites this paper
• Case of Advanced Recurrent Glioblastoma Successfully Treated with Monoterpene Perillyl Alcohol by Intranasal Administration

  2011cites this paper
• Argonaute2 is a potential target for siRNA-based cancer therapy for HT1080 human fibrosarcoma

  2011cites this paper
• The Genomic and Proteomic Content of Cancer Cell-Derived Exosomes

  2011cites this paper
• Cryptic parasite revealed improved prospects for treatment and control of human cryptosporidiosis through advanced technologies.

  2011cites this paper
• Updating progress in sarcoma therapy with mTOR inhibitors.

  2011cites this paper
• Coating cells with cationic silica–magnetite nanocomposites for rapid purification of integral plasma membrane proteins

  2011cites this paper
• Small molecule inhibition of protein depalmitoylation as a new approach towards downregulation of oncogenic Ras signalling.

  2011cites this paper
• Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.

  2011cites this paper
• A Review of Antisense Therapeutic Interventions for Molecular Biological Targets in Various Diseases

  2011cites this paper
• Improving VSV virotherapy in chronic lymphocytic leukemia with small-molecule BCL-2 inhibitors

  2011cites this paper
• Ubiquitination

  2011cites this paper
• ETS1 AND ETS2 ROLE IN RAS ONCOGENIC TRANSFORMATION IN MOUSE EMBRYONIC FIBROBLASTS

  2010influential citation
• The Deubiquitinating Enzyme USP17 Blocks N-Ras Membrane Trafficking and Activation but Leaves K-Ras Unaffected

  2010cites this paper
• Induction of p53 Dependent Cellular Senescence Through HdmX Inhibition or YPEL3 Expression

  2010cites this paper
• Expression analysis of Akt and MAPK signaling pathways in lung tissue of patients with idiopathic pulmonary fibrosis (IPF)

  2010cites this paper
• Cancer esearch apeutics , Targets , and Chemical Biology 3 CA Mutation Uncouples Tumor Growth and Cyclin D 1 R ulation from MEK / ERK and Mutant KRAS Signaling

  2010cites this paper
• New druggable targets in the Ras pathway?

  2010cites this paper
• Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines.

  2010cites this paper
• Requirement of the NF- κ B Subunit p65/RelA for K-Ras – Induced Lung Tumorigenesis

  2010cites this paper
• The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors

  2010cites this paper
• Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements

  2010cites this paper
• Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis.

  2010cites this paper
• A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

  2010cites this paper
• Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas.

  2010cites this paper
• PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.

  2010cites this paper
• Genetic Alterations in the Phosphatidylinositol-3 Kinase/Akt Pathway in Thyroid Cancer

  2010cites this paper
• Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination

  2010cites this paper
• Apoptosis‐inducing effects of Morinda citrifolia L. and doxorubicin on the Ehrlich ascites tumor in Balb‐c mice

  2009cites this paper
• Self-assembly of lithographically patterned nanoparticles.

  2009cites this paper
• PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.

  2009cites this paper
• Lessons from Mouse Models of Thyroid Cancer

  2009cites this paper
• Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines

  2009cites this paper
• Modeling Thyroid Cancer in the Mouse

  2009cites this paper
• Efficacy of IGFBP 7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines

  2009cites this paper
• Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D).

  2009cites this paper
• Noonan, Costello and cardio–facio–cutaneous syndromes: dysregulation of the Ras–MAPK pathway

  2008cites this paper
• c-Myc Inhibits Ras-Mediated Differentiation of Pheochromocytoma Cells by Blocking c-Jun Up-Regulation

  2008cites this paper
• BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.

  2008cites this paper
• Identification of molecular targets of oncogenic NRAs and BRAF involved in regulation of melanoma cell proliferation

  2007cites this paper
• HRAS and the Costello syndrome

  2007influential citation
• Clinical activity of tipifarnib in hematologic malignancies

  2007cites this paper